The D2 subtype of dopamine receptor has been widely implicated in the pathogenesis of schizophrenia. Early evidence supporting an association between the Cys311Ser polymorphism of the D2 receptor gene (DRD2) and schizophrenia was subsequently refuted and, eventually, dismissed. From all 24 published case-control studies, we calculated a pooled estimate of this association. The pooled odds ratio was 1.3 for the Cys allele, which was highly significant (P = 0.007). The odds ratio derived from each study was unrelated to the ethnicity or gender composition of the sample, or the age of the control group. There was no evidence of publication bias or excessive influence attributable to any given study. Although more familybased studies are needed to confirm this relation, our results provide strong evidence that DRD2 influences susceptibility to schizophrenia. Molecular Psychiatry (2003) 8, 911-915. doi:10.1038/sj.mp.4001321
Dopamine system dysfunction has been widely implicated in the pathogenesis of schizophrenia. The most effective known treatments for schizophrenia are those that principally antagonize the D2 subtype of dopamine receptor. 1 In fact, the D2 receptorbinding efficacy of neuroleptics is highly correlated with their ability to ameliorate symptoms. 2 Furthermore, D2 receptor-binding density is increased in the brains of schizophrenic patients. 2 When a functional variant of the D2 receptor gene (DRD2) was discovered 3 and found to be associated with the disorder, 4 a role for DRD2 in the genesis of schizophrenia was postulated. This mutation, a C-to-G transversion in codon 311, results in the substitution of cysteine (Cys) for serine (Ser) in the protein and, consequently, alters the physiology and function of the receptor. 3 For example, the Cys variant of the D2 receptor has approximately half of the affinity for dopamine as that exhibited by the wild-type receptor. In addition, signal transduction in cells expressing this variant is reduced by 44%, an effect that is not because of impaired G-protein coupling but which may be mediated by lower efficiency of the variant-containing protein in activating the a subunit of the associated G-protein heterotrimer. 5 Although the early evidence for association noted by Arinami et al 4 was strong, 21 of 22 subsequent studies of this putative association with schizophrenia failed to detect a significant relation. Thus, the initial finding of association has come to be regarded as a type-I inferential error. 6 Yet, it is uncertain if this failure to identify consistently an association has been because of the low power of individual studies to detect a small effect, etiological heterogeneity, or random error in the absence of a true effect. To derive a powerful estimate of the true association between the Cys311Ser DRD2 polymorphism and schizophrenia, we performed a meta-analysis of all 24 published case-control studies in which this relation was examined.
Materials and methods

Literature search
To identify studies eligible for meta-analysis, MED-LINE citations (January, 1966 -September, 2002 were surveyed using the National Library of Medicine's PubMed on-line search engine with 'schizophrenia' and 'DRD2' as keywords. The retrieved abstracts were read to identify studies that examined the allelic association between a polymorphism within the DRD2 gene and schizophrenia. Studies of this type were then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. All references cited in these works were also reviewed to identify additional works not indexed by MEDLINE.
Inclusion criteria
Only those studies examining the DRD2 Cys311Ser polymorphism were included in the meta-analysis. Furthermore, studies had to meet all of the following criteria: (1) be published in a peer-reviewed journal, (2) present original data, and (3) provide enough data to calculate an effect size. Of the studies that were retrieved through the literature search and retained by virtue of examining the correct polymorphism, none was excluded based on these conditions. The application of these criteria yielded 24 studies eligible for meta-analysis, of which 23 used case-control designs, 3, 4, and one utilized both a case-control and a family-based strategy. 6 Only the case-control samples were included in the metaanalysis.
Coding of study characteristics
To delineate potential moderating influences of various sample characteristics on the size of the effects obtained in the case-control studies under consideration, each study was coded on the following variables: (1) the ethnicity of the sample, (2) the mean age of the control group, and (3) a gender index (calculated as (female case/males case)/ (female controls/male controls)). These descriptive characteristics of the studies are presented in Table 1 .
Statistics
Data from each case-control study were used to construct a two-by-two table in which subjects were classified by diagnostic category (case or control) and allele (Cys or Ser). The strength of association in these two-by-two tables was summarized using the odds ratio (OR), in which Cys was assigned as the risk allele based on the initial report of significant association, 4 and an OR41.0 indicated a positive association between this allele and schizophrenia. For case-control studies, the OR estimates the relative risk, which represents the increase in the probability of observing the Cys allele in cases relative to controls.
Case-control studies were analyzed by random effects meta-analysis. The pooled OR was calculated according to the methods of DerSimonian and Laird, 27 and its 95% confidence interval (CI) was constructed using Woolf's 28 method. The heterogeneity of the group of ORs was assessed using a w 2 test of goodness of fit, and the significance of the pooled OR was determined by the z test. The influence of individual studies on the pooled OR was determined by sequentially removing each study and recalculating the pooled OR and 95% CI.
Publication bias within the group of ORs was assessed by the method of Egger et al, 29 in which the standard normal deviate (SND) of the OR (z) is regressed on the precision of the OR (POR, the inverse of the standard error of the OR). Since POR increases with sample size, the regression of z on POR should run through the origin in the absence of bias (ie, small samples with low precision have large standard errors and small SNDs, whereas large samples with high precision have small standard errors and large SNDs). The slope (b) of the regression line indicates the size and direction of association and, in the presence of bias, the intercept of the regression (a) will be significantly different from zero, as determined by the t-test. The moderating influences of sample ethnicity, age of the control group, and gender index on the OR derived from each case-control study were assessed by multiple regression. The type-I error rate was set at 0.05. All statistical analyses were conducted using Stata 7.0 (Stata Corporation; College Station, TX, USA).
Results
There was no evidence for heterogeneity (w 2 (23) ¼ 20.01, P ¼ 0.641) among the ORs derived from the 24 casecontrol studies ( Table 2 ). The pooled OR for the Cys allele, derived from 3733 cases and 5373 controls, was small (OR ¼ 1.3, 95% CI ¼ 1.1-1.6), but was highly significant (z ¼ 2.68, P ¼ 0.007). There was no evidence of publication bias within this group of studies (a ¼ À0.40, t ¼ À0.75, P ¼ 0.463), as the 95% CI around the intercept of the regression of z on POR encompassed the origin (Figure 1 ). Sequential removal and replacement of individual studies from the calculation of the pooled OR produced estimates ranging from 1.2 to 1.4 and 95% CIs that never included an OR of 1.0, suggesting that no single study had excessive influence on the significance of the pooled OR. The OR derived from each study was not significantly affected by the ethnicity of the sample (b ¼ 0.43, z ¼ 1.46, P ¼ 0.144), the gender composition of the sample (b ¼ 0.12, z ¼ 0.37, P ¼ 0.713), or the age Table 2 Meta-analysis of case-control studies of the association between the DRD2 Cys311Ser polymorphism and schizophrenia
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Discussion
The results of this meta-analysis clearly identify the Cys allele of the Cys311Ser polymorphism of DRD2 as a risk factor for schizophrenia. The potential assignment of DRD2 as a universal susceptibility gene for schizophrenia is uncomplicated by heterogeneity among studies, ethnic differences in association, publication bias, or the excessive influence of any single study. Although the increase in schizophrenia liability associated with the Cys allele is small (OR ¼ 1.3) and the proportion of schizophrenia cases attributable to this variant is low (population attributable fraction ¼ 0.009), the risk associated with this polymorphism is actually greater than that for either HTR2A or DRD3, two widely recognized schizophrenia susceptibility genes. 30, 31 Thus, the identification of this schizophrenia risk factor significantly improves our understanding of the genetic contribution to the disorder, which, to date, is still quite limited. These findings also reinforce the notion that pooled analyses like that presented here and elsewhere 30, 31 may be the best way to elucidate the numerous genes of small effect that may predispose to schizophrenia and other multifactorial polygenic disorders.
The association between the Cys allele and schizophrenia noted by Arinami et al 4 was not the strongest reported, but their study is one of only two that found a statistically significant relation, and was the earliest to do so. Most, if not all, of the subsequent studies of this association may have been constructed to detect a significant effect of the same magnitude as that reported in this early study. Unfortunately, this strategy may have equipped most of the later studies with insufficient power to detect a much smaller, but probably much more accurate, measure of the association. Thus, while the 24 studies summarized here had, on average, 55.7% power to detect an association as large as that observed by Arinami et al (OR ¼ 3.1), 4 the average power to detect the pooled OR we have reported (OR ¼ 1.3) was only 7.5%.
In conclusion, while an association as large as that initially reported is unlikely, these findings suggest that a weaker, but true, association between schizophrenia and DRD2 does exist. It is not yet clear if the Cys allele confers excess risk for schizophrenia directly or if it is in linkage disequilibrium with a causative allele at another locus. Family-based studies of this association, of which only one currently exists (OR ¼ 1.7), 6 should be considered a high priority if this association is to be confirmed, validated, and widely recognized.
